The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
Katherine L. Osusky(Vanderbilt University), Ling Geng(Vanderbilt University), Dennis E. Hallahan(Washington University in St. Louis), Yu Shyr(Vanderbilt University), Fei Ye(Army Medical University), Allie Fu(Vanderbilt University)
Cited by 154
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia
|New England Journal of Medicine|2017|640
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|572
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
|Cancer Immunology Research|2016|493